title: Regulating TRAIL receptor-induced cell death at the membrane : a deadly discussion.
abstract: The use of TRAIL/APO2L and monoclonal antibodies targeting TRAIL receptors for cancer therapy holds great promise, due to their ability to restore cancer cell sensitivity to apoptosis in association with conventional chemotherapeutic drugs in a large variety of tumors. TRAIL-induced cell death is tightly regulated right from the membrane and at the DISC (Death-Inducing Signaling Complex) level. The following patent and literature review aims to present and highlight recent findings of the deadly discussion that determines tumor cell fate upon TRAIL engagement.
authors.affiliation: INSERM, U866, Dijon, F-21079 France; Faculty of Medicine and Pharmacy, University of Bourgogne, Dijon, F-21079 France. omicheau@u-bourgogne.fr
authors.forename: Sarah
authors.initials: S
authors.lastname: Shirley
authors.forename: Alexandre
authors.initials: A
authors.lastname: Morizot
authors.forename: Olivier
authors.initials: O
authors.lastname: Micheau
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000235:genetics / Q000502:physiology*; D051017:Apoptosis Regulatory Proteins / Q000235:genetics / Q000378:metabolism / Q000502:physiology; D016923:Cell Death / Q000235:genetics / Q000502:physiology; D002462:Cell Membrane / Q000378:metabolism* / Q000473:pathology; D006801:Humans; D008954:Models, Biological; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D015398:Signal Transduction / Q000235:genetics / Q000502:physiology
chemical_list: D051017:Apoptosis Regulatory Proteins; D053220:Receptors, TNF-Related Apoptosis-Inducing Ligand